Personalized Obesity Prevention and Treatment System

A next-generation system integrating steroid sulfatase inhibitors with machine learning algorithms and genomic data for tailored treatment of obesity and lipid-related metabolic disorders, offering a paradigm shift in personalized medicine.

The original patent disclosed a functional composition for preventing or treating obesity or lipid-related metabolic disease using irosustat. However, the treatment outcomes varied among individuals, and there was a need for a more personalized approach. The new inventive concept addresses this limitation by incorporating machine learning algorithms, genomic data, and wearable devices to provide real-time monitoring and tailored treatment.

The system comprises a steroid sulfatase inhibitor, a machine learning algorithm, and a genomic data repository. The algorithm predicts individualized treatment outcomes based on genomic data and real-time monitoring of lipid metabolism using wearable devices. The system also includes a composition for synergistic prevention or treatment of obesity and lipid-related metabolic disease, comprising a steroid sulfatase inhibitor and a gut microbiome modulator. Additionally, a device for non-invasive, transdermal delivery of the steroid sulfatase inhibitor is included. The computer-implemented method for predicting the efficacy of the steroid sulfatase inhibitor in treating obesity or lipid-related metabolic disease based on patient-specific data and machine learning algorithms completes the system.

The new claims introduce a paradigm shift by integrating machine learning algorithms, genomic data, and wearable devices to provide personalized treatment outcomes, which is not obvious from the original patent. The combination of these elements and the specific implementation details demonstrate a novel and non-obvious inventive concept.

Alternative embodiments may include using different types of machine learning algorithms, incorporating additional data sources such as electronic health records, or developing new formulations of the steroid sulfatase inhibitor. Variations of the system could include targeting specific populations, such as pediatric or geriatric patients, or integrating with existing healthcare infrastructure.

The personalized obesity prevention and treatment system has significant commercial potential in the healthcare industry, particularly in the fields of precision medicine and digital health. The target market includes pharmaceutical companies, healthcare providers, and patients seeking personalized treatment options for obesity and lipid-related metabolic disorders.